

## Research Article

# Characterization and Expression of ATP P2X<sub>4</sub> Receptor From Embryonic Chick Skeletal Muscle

Xuenong Bo,<sup>1,2</sup> Min Liu,<sup>1</sup> Ralf Schoepfer,<sup>2</sup> and Geoffrey Burnstock<sup>1\*</sup>

<sup>1</sup>Autonomic Neuroscience Institute, Royal Free and University College Hospital School of Medicine, London, UK

<sup>2</sup>Wellcome Laboratory for Molecular Pharmacology and Department of Pharmacology, University College London, London, UK

Strategy, Management and Health Policy				
Venture Capital Enabling Technology	Preclinical Research	Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics	Clinical Development Phases I-III Regulatory, Quality, Manufacturing	Postmarketing Phase IV

**ABSTRACT** Previous pharmacological experiments have indicated the existence of ATP P2X receptors in chick embryonic skeletal muscles. In this study we cloned a P2X<sub>4</sub>-like cDNA encoding a protein of 385 amino acids, which shares 75% and 76% identity with rat and human P2X<sub>4</sub> receptors, respectively. Functional studies of this cP2X<sub>4</sub> receptor expressed in *Xenopus* oocytes showed that ATP induced a fast inward current, which was partially desensitized upon prolonged application of ATP. The ATP-induced currents were concentration-dependent, with an EC<sub>50</sub> of 9.5 μM. Adenosine 5'-O-(thio)triphosphate and 2-methylthioATP very weak agonists. α,β-methyleneATP was almost inactive. In contrast to their potentiating effects on recombinant rat P2X<sub>4</sub> receptors, both suramin and pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid partially blocked ATP-induced currents. TrinitrophenylATP was able to block ATP-induced response completely, with an IC<sub>50</sub> of 4.7 μM. Northern blot and RT-PCR analysis showed that cP2X<sub>4</sub> mRNAs were mainly expressed in skeletal muscle, brain, and gizzard of day 10 chick embryos. Lower levels of expression were also detected in liver, heart, and retina. Whole-mount in situ hybridization showed that cP2X<sub>4</sub> mRNAs were expressed in the brain, spinal cord, notochord, gizzard, and skeletal muscle. The physiological functions of cP2X<sub>4</sub> receptors in embryonic skeletal muscle remain unclear at present. Drug Dev. Res. 53:22–28, 2001. © 2001 Wiley-Liss, Inc.

**Key words:** purinoceptor; P2X receptor; ATP; skeletal muscle

## INTRODUCTION

Extracellular ATP induces biological effects via two types of receptors, fast ligand-gated ion channel receptors (P2X), and G-protein-coupled receptors (P2Y) [Abbraccio, and Burnstock, 1994]. P2X and P2Y receptor subtypes have been identified in many cell types and found to mediate a variety of biological activities [Burnstock, 1997; Ralevic and Burnstock, 1998]. So far, seven P2X receptor subtypes (or subunits) have been cloned from mammalian tissues [MacKenzie et al., 1999]. Recently, we cloned a novel P2X receptor from chick embryonic skeletal muscle [Bo et al., 2000], which is tentatively named cP2X<sub>8</sub> receptor.

Rat P2X<sub>4</sub> receptor was cloned in our laboratory from rat hippocampus cDNA library [Bo et al., 1995]. It was

also cloned from superior cervical ganglion cDNA library [Buell et al., 1996], whole brain cDNA libraries [Séguéla et al., 1996; Soto et al., 1996], and pancreatic islet cDNA library [Wang et al., 1996]. Rat P2X<sub>4</sub> receptor has wide tissue distribution in both central nervous tissues and peripheral tissues [Bo et al., 1995; Buell et al., 1996; Soto et al., 1996; Xiang et al., 1998]. Its expression has been

Contract grant sponsor: The Wellcome Trust.

\*Correspondence to: Geoffrey Burnstock, Autonomic Neuroscience Institute, Royal Free and University College Hospital School of Medicine, Rowland Hill Street, London NW3 2PF, UK. E-mail: g.burnstock@ucl.ac.uk

Received 1 March 2001; accepted 17 April 2001

detected in epithelia of submandibular glands, where P2X<sub>4</sub>-like receptor-mediated currents have been observed, indicating the existence of possible functional homomeric receptors [Buell et al., 1996]. The formation of functional heteromeric receptors of P2X<sub>4</sub> with P2X<sub>6</sub> in *Xenopus* oocytes has been reported [Lê et al., 1998]. The P2X<sub>4+6</sub> receptors showed different functional properties from both homomeric P2X<sub>4</sub> and P2X<sub>6</sub> receptors, such as increased sensitivity to  $\alpha,\beta$ -methyleneATP and to the antagonist suramin. However, the existence of native P2X<sub>4+6</sub> receptors remains to be confirmed.

It was observed many years ago that ATP could activate cation channels in cultured chick myoblasts and myotubes [Kolb and Wakelam, 1983]. Later, Hume and Honig [1996] showed that ATP induced depolarization and contraction in chick myotubes. The existence of P2X receptors in the embryonic chick skeletal muscle is conspicuous. Two years ago, we started to clone the P2X receptors from embryonic chick skeletal muscle. Using RT-PCR, we obtained two cDNA fragments: one encodes a partial sequence of the above-mentioned cP2X<sub>8</sub> receptors, while the other encodes a partial sequence closely related to P2X<sub>4</sub> receptors. The full-length P2X<sub>4</sub>-like cDNA was cloned and the encoded receptor protein was expressed in *Xenopus* oocytes for functional studies. The expression of its mRNA transcripts in chick embryonic tissues was studied with Northern blot hybridization, RT-PCR analysis, and whole-mount in situ hybridization. A similar cDNA was cloned from embryonic chick heart and brain [Ruppelt et al., 1999]; however, an alignment of these two encoded proteins revealed that two amino acid residues are different. In this article, we report the full-length cP2X<sub>4</sub> cDNA sequence, including the polyA<sup>+</sup> tail, more functional characterization data on recombinant cP2X<sub>4</sub> receptor, and its expression in chick embryonic tissues.

## MATERIALS AND METHODS

### Isolation of cDNA Clone

PolyA<sup>+</sup> mRNAs were isolated from skeletal muscles of six day-10 White Leghorn chick embryos using FastTrack 2.0 kit (Invitrogen BV, Leek, The Netherlands). Two degenerated oligonucleotide primers (sense: ACCTGTGAGATSTBKRSYTGCTGCC, and anti-sense: ARTRHKTGGCDRWCCCTGAARTTGTASC) based on the sequences of the seven cloned rat P2X receptors were ordered from Sigma-Genosys (Cambridge, UK). First-strand cDNAs were synthesized with oligo(dT) and random primers using Superscript II RNase H<sup>-</sup> reverse transcriptase (Life Technologies, Inchinnan Business Park, UK). Touch-down PCR was performed on the first-strand cDNAs using the degenerated primers. The annealing temperature was reduced from 65°C to 55°C in 20 cycles (-0.5°C per cycle) and a further 30 cycles

were run at an annealing temperature of 55°C. PCR fragments of the predicted sizes were purified and subcloned into pCR II using TOPO TA Cloning kit (Invitrogen BV) and sequenced. Two fragments related to P2X receptors were identified.

To isolate the full-length clone of the P2X receptor cDNA, a chick embryonic skeletal muscle cDNA library was constructed using a kit (Stratagene Europe, The Netherlands) [Bo et al., 2000]. The cDNA library was screened with <sup>32</sup>P-labeled probe derived from the PCR fragment. The probe was labeled using Prime-IT II kit (Stratagene Europe). Hybridization was carried out at 42°C in a buffer containing 20% formamide. Low stringency washing was controlled by the final wash in 1 × SSPE at 45°C. Positive clones were subjected to secondary screening. Totally isolated clones were obtained and the phagemid pBluescript SK(-) containing cDNA inserts was excised from Lambda ZAP II vector and transformed into *E. coli* for amplification. cDNA inserts were sequenced in both directions.

### Electrophysiology

To study the electrophysiological and pharmacological properties of the encoded receptor, cRNA was synthesized and injected into defolliculated *Xenopus* oocytes (23 nl of cRNA at 100 µg/ml). Injected oocytes were analyzed in the two-electrode voltage clamp configuration as described previously [Bo et al., 1995].

### Northern Blot Analysis

PolyA<sup>+</sup> mRNAs were isolated from fresh tissues of day 10 chick embryos using the FastTrack 2.0 kit. PolyA<sup>+</sup> mRNAs (3 µg) were size-separated through a 1.5% agarose gel containing formaldehyde and transferred onto nylon membranes (Hybond N, Amersham-Pharmacia Biotech, Amersham, UK). The cDNA of the coded region was radiolabeled as described above and used as probe. Hybridization was carried out in a buffer with 50% formamide overnight at 42°C and the stringency was controlled by a final wash of the membrane in 0.3 × SSPE at 65°C. The membrane was exposed to X-ray film for 3 days.

### RT-PCR

The first-strand cDNAs were synthesized with Superscript II RNase H<sup>-</sup> reverse transcriptase from 0.8 µg polyA<sup>+</sup> mRNAs. A sense primer with the sequence of AGAGCTGCTTCCCCTGCGTG and an anti-sense primer with a sequence of GGTCTCACAGCAGGGTCACAG were used to amplify the cDNAs. PCR was performed using the touch-down method with an initial annealing temperature of 70°C and a reduction of 0.5°C per cycle for the first 10 cycles. The second stage was performed with an annealing temperature of 65°C for 20 cycles. PCR products were identified in a 1.5% agarose gel.

### Whole-Mount In Situ Hybridization

The first 400 bp of the cDNA open reading frame was subcloned into pCRII vector (Invitrogen). Both sense and antisense cRNA probes were synthesized with the DIG-RNA labeling kit (Roche Diagnostics, Lewes, UK). Day 3, day 4, and day 6 chick embryos were fixed in 4% paraformaldehyde overnight. Whole-mount in situ hybridization was performed according to the protocol described by Nieto et al. [1996]. Prehybridization was carried out in a buffer containing 50% formamide at 55°C for 4 h, followed by overnight hybridization at 55°C for day 3 and day 4 embryos and 3 days for day 6 embryos. Final wash was in 2 × SSC with 50% formamide at 55°C for 2 × 60 min. Hybridization signals were revealed with anti-DIG-alkaline phosphatase antibody staining (DigNucleic Acid Detection Kit, Roche). Whole embryos were photographed and then embedded in gelatin-albumin gel. Sections (100 μm thick) of the embryos were cut with a vibratome.

## RESULTS

### Cloning of the cP2X<sub>4</sub> Receptor

RT-PCR with degenerated primers produced a cDNA fragment of 427 bp. Alignment of this cDNA fragment with the cloned P2X receptors showed that it was

closely related to P2X<sub>4</sub> receptors. Screening of the embryonic chick skeletal muscle cDNA library identified two full-length cDNA clones with 1,803 bp (including the polyA<sup>+</sup> tail) (Fig. 1). The open reading frame encodes a protein of 385 amino acids (Fig. 1). The calculated molecular weight of the protein is 43.4 kDa. The P2X receptor sequence has the two putative transmembrane domains and the 10 conserved cysteine residues in the extracellular loop like all other cloned P2X receptors. The deduced amino acid sequence of cP2X<sub>4</sub> shares 75% identity with rat and mouse P2X<sub>4</sub>, and 76% with human P2X<sub>4</sub>. The alignment of their amino acid sequences is shown in Figure 2. For other receptors, the percentage of identity is as follows: 46% with rat P2X<sub>1</sub>, 38% with rat P2X<sub>2</sub>, 42% with rat P2X<sub>3</sub>, 44% with rat P2X<sub>5</sub>, 43% with rat P2X<sub>6</sub>, 29% with P2X<sub>7</sub>, and 53% with chick P2X<sub>8</sub>. The high percentage of identity of the encoded protein with the P2X<sub>4</sub> receptors indicates this receptor is an ortholog of P2X<sub>4</sub> receptors.

### Functional Characterization of Recombinant Receptors


Application of ATP on *Xenopus* oocytes injected with cP2X<sub>4</sub> RNA produced a fast inward current (Fig. 3A), which partially desensitized the receptors. The degree of desensitization depended on the concentration

```

1 CC ATG GCT GCG TGC TGC GGG GCT GTG CGC GGC TTC CTC TTC GAG TAC GAC ACC CCC CGC ATC GTG CTG ATC CGC 74
1 H A A C C G G A V R G F L F E Y D T P R I V L I R 24
75 AGC CGC AAA GTC GGG CTG ATC AAC CGC GGC GTG CAG CTC GCC ATC CTC GCC TAC GTG ATC GGC TGG GTC TTT CTG 149
25 S R K V G L I N R A V Q L A I L A Y V I G W V F L 49
150 TGG GAG AAG GGC TAC CAG GAA ACA GAT TOC GTG GTC AGT TCT GTA ACC ACG AAG GTG AAA GGG GTA ACG ATG ACA 224
50 W E K G Y Q E T D S V V S S V T T K V K G V T M T 74
225 AAC ACA TCC ACC TTG GGA TCC AGG ATC TGG GAT GTA GCT GAC TAC GTC ATC CCT CCC CAG GAG AAG AAC GCT GTG 299
75 N T S T L G S R I W D V A D Y V I P P Q E K N A V 99
300 TTT GTC ATG ACC AAC ATG ATA TTC ACA CTG AAC CAG AGC CAA AGC CAC TGC CCA GAG CTT CCA GAT GAT AAC ACA 374
100 F V M T N I F T L N Q S Q H C P E L P D N T 124
375 GAG TGC AAC AAC AGC AGC TGC GTT CCA GGA TAT GTC AGC ACC CAC AGC AAT GGT ATC CAG ACC GGG GCG TGC 449
125 E C N N N S S C V P G Y V S T H S N G I Q T G A C 149
450 ATA CCG TAC AAC AGC AGC ATC AAG ACC TGT GAA GTC TTT GCA TGG TGC OCT GTG GAG GAT GAC TAT CAC ATA CCC 524
150 I P Y N S I K T C E A W C F V E D D Y H I P 174
525 AAT CCG CCA TTC TTG CAA GGA GCT GAG AAC TTC ACC ATT CTG GTA AAG AAC AAC ATT TGG TAT CCC AAG TTC AAC 599
175 N P A F L Q I F T I L V K N N I W Y P K F N 199
600 TTC AGC AAG CGA AAC ATC CTC CCC ACT TTC AGT TCC TCT TAT CTC AAG AAC TGC ATC TAT GAT GCC CAG ACA GAT 674
200 F S K R N I L P T F S S S Y L K N C I Y D A Q T D 224
675 CCC TTC TGC CCT ATC TTT CGT CTG GGG AAA ATA GTT GAA GCT GCA GGG CAG AAC TTC CAG GAA ATG GCT GTG GAG 749
225 P F C P I F R L G K I V E A A G N F Q E M A V E 249
750 GGT GGG GTC ATG GGG CTG CAG ATC AAC TGG GAC TGC AAC CTC GAC AGA GCT GCT TCC CAC TGC GTG CCC AAG TAT 824
250 G G V M G L Q I N W D C N L D A S H C V P K Y 274
825 TCC TTC CGG CGC CTG GAC AAC AAG GAC TCT GCC AAC ACT ATC TCA CCT GGG TAC AAC TTC AGG TTT GCA AAA TAC 899
275 S F R R L D N K D S A N T I S P G Y N F R F A K Y 299
900 TAC AAG GAT AGT AGT GGC ATT GAA ACA CGA ACG CTT ATC AAA GCT TAT GGC ATC CGC CTT GAT ATC ATA GIG TTT 974
300 Y K D S S G I A C R T L I K A Y G C I R L D I V F 324
975 GGA AAG GCA GGA AAA TTT GAT GTA ATT CCT ACC ATG ATT AAC ATT GGC TCT GGC TTA GCG CTG TTT GGA GTG GCA 1049
325 G K A G K F D V I P T H I N I G S G L A L F G V A 349
1050 ACA GTG CTG TGT GAC ATC GTT GTC CTG TAC TGC ATG AAA AAG AGG TAC TTC TAT CGG GAG AAG AAG TAC AAA TAC 1124
350 T V L C D I V V L Y C M K K R Y F Y R E K K Y K Y 374
1125 GTG GAG GAT TAT GAA CTG GGC ACA AGT GAG ACA TAA GGAAGACTCCTGACCTCCTGCTGCTGCTGTAATGTTACTGTGACCCCTGC 1210
375 V E D Y E L L G T S E T *
1211 TGTGAGACCTACCTCTCCCTTGGAAAGGAAAGGGGAAACAGAACCTAAGAAAGGGACCTCTTCTATTACTCATCCCTTTTGTGCGGCAGAACCAAGAGGA 1310
1311 GAACCGGATCTGCTCTCTGTCTGTCTTCCAGGTTAACTGCACCAAGCCCATACAGAGCCTTGTGGCTTCGTGCCAGACATCTGCACCTAGCAAGCCTGG 1410
1411 GACAGGGACTGCCCCGTCTTGTCAITTCAGCAGTCCCTCCCTGAGCTCAGTGGTAGTAGCAGTGAAGCCCTTGAAGAGGCACAGACTCTTCTTAGAG 1510
1511 GGAACATGGCCCATGACATGTGTGCCTACCCTGGGAGAGCAGTCTTCTGCTGTCCAGGATCACAGTGTCTAGGTGAGACCCGCTGCTATTAATTGCA 1610
1611 TCTCCAAGCTCTAGTGGCCACAGCTTGAGACAAAAGCAGTGTCTGATTCCATTGTGCTATGGTAAATAGCTTACTGGCTACAGGATTTCTTATCTGTGTTG 1710
1711 TCTGGCTAATACCACACTACACTGGAATTCTGTTTCTCATAAAATGTTACTCTCTACCAGCTCTCTTGGAGTCCCTGCAAAAAAAAAAAAAAAAAA 1803

```

**Fig. 1.** cDNA sequence of cP2X<sub>4</sub> receptor and the deduced amino acid sequence. The nucleotide sequence of cP2X<sub>4</sub> cDNA has been submitted to the GenBank database with accession number AF218449.




**Fig. 2.** Alignment of the deduced amino acid sequence of cP2X<sub>4</sub> receptor with rat, mouse, and human P2X<sub>4</sub> receptors. The two putative transmembrane domains are indicated by bars underneath. The ten conserved cysteine residues on the extracellular loop are marked by an asterisk.

of ATP used. With 3.3 and 10  $\mu$ M ATP, the spikes were usually small; at higher concentration of ATP the desensitization was much more obvious. The recovery time from desensitization also depended on the concentration of ATP applied, ranging from 5 min at 3.3  $\mu$ M to 15 min at 100  $\mu$ M. Construction of a concentration-response curve for ATP (not shown) yielded an EC<sub>50</sub> value of  $9.5 \pm 1.3 \mu$ M.

Replacement of Ca<sup>2+</sup> in the perfusion buffer with Ba<sup>2+</sup> did not change the characteristics of the ATP-induced inward currents (Fig. 3B). However, when Ca<sup>2+</sup> concentration in the perfusion buffer was reduced from 1.8 mM to 0.3 mM, the ATP-induced currents were much smaller, with the obvious disappearance of the fast-desensitizing component (Fig. 3B).

In addition to ATP, many other ATP receptor-active compounds were also tested. 2-MethylthioATP and adenosine 5'-O-(thio)triphosphate (ATP $\gamma$ S) were weak agonists for cP2X<sub>4</sub> receptors, inducing inward currents of about 20–60 nA at 100  $\mu$ M, which were much smaller than that of ATP (average of 600 nA at 100  $\mu$ M) (Fig. 3C).  $\alpha$ , $\beta$ -MethyleneATP was even weaker than 2-methylthioATP (Fig. 3C). No detectable response was recorded from  $\beta$ , $\gamma$ -methyleneATP, UTP, GTP, TTP, ADP, AMP, adenosine, and diadenosine tetraphosphate at concentrations up to 100  $\mu$ M.

Suramin or pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), each at 100  $\mu$ M, did not pro-




**Fig. 3.** Functional expression of recombinant cP2X<sub>4</sub> receptors in *Xenopus* oocytes. **A:** Inward currents induced by different concentrations of ATP in cP2X<sub>4</sub> cRNA injected *Xenopus* oocytes in 1.8 mM Ca<sup>2+</sup> medium. **B:** Comparison of the currents induced by 100  $\mu$ M ATP in 1.8 mM Ca<sup>2+</sup>, 1.8 mM Ba<sup>2+</sup>, and 0.3 mM Ca<sup>2+</sup> medium. **C:** Currents induced by 100  $\mu$ M  $\alpha$ , $\beta$ -methyleneATP ( $\alpha$ , $\beta$ -MeATP), 2-methylthioATP (2-MeSATP), and ATP $\gamma$ S. **D:** Currents induced by ATP (100  $\mu$ M) were partially blocked by 100  $\mu$ M PPADS or suramin.

duce any detectable response in oocytes expressing cP2X<sub>4</sub> receptors. Both were shown to partially block ATP-induced currents (Fig. 3D). A recently identified P2X receptor antagonist, 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP) [Mockett et al., 1994; Virginio et al., 1998], could completely block the ATP-induced currents (Fig. 4). Construction of a concentration-inhibition curve yielded an IC<sub>50</sub> value of  $4.74 \pm 0.14 \mu$ M for TNP-ATP.

### Tissue Distribution

Northern blot hybridization analysis revealed the expression of cP2X<sub>4</sub> mRNA transcripts of about 1.9 kb in day 10 chick embryonic tissues (Fig. 5A). The skeletal muscle, brain, and gizzard showed the highest level of expression. Lower levels of expression were detected in




**Fig. 4.** Inhibition of ATP-induced currents via recombinant cP2X<sub>4</sub> receptors in *Xenopus* oocytes by trinitrophenylATP (TNP-ATP). **A:** Inhibition of 10 μM ATP-induced current by 10 μM TNP-ATP. **B:** Concentration-inhibition curve of ATP-induced currents by TNP-ATP, with an IC<sub>50</sub> of 4.74 ± 0.14 μM.

liver, heart, and retina. RT-PCR assays revealed a similar pattern of expression (Fig. 5B).

Whole-mount in situ hybridization on day 3, day 4, and day 6 chick embryos showed a wide distribution of cP2X<sub>4</sub> mRNA transcripts (Fig. 6). The signals generated were lower compared with that of cP2X<sub>8</sub> probes. In day 3 and day 4 embryos, hybridization signals were observed in the brain and the ventral part of the spinal cord. They were also present in notochord, esophagus, gizzard, and heart (Fig. 6). In day 6 embryo, faint signals in myotomes and premuscle mass were observed; however, they were not as strong as that detected with cP2X<sub>8</sub> probes at the same stage of development.

## DISCUSSION


The P2X<sub>4</sub> receptor is the most widely distributed receptor of the P2X family. It is also the most abundant in the central nervous system. Following the cloning of rat P2X<sub>4</sub> receptors [Bo et al., 1995], the human and mouse orthologs of P2X<sub>4</sub> receptors have also been cloned from brain cDNA libraries [Garcia-Guzman et al., 1997; Townsend-Nicholson et al., 1999]. A partial P2X<sub>4</sub> cDNA sequence was isolated from rabbit osteoclast cDNA library [Naemsch et al., 1999]. Last year, a chick P2X<sub>4</sub> cDNA was cloned from embryonic chick heart and brain [Ruppelt et al., 1999] (GenBank accession number Y18008). Alignment of the deduced amino acid sequence of Clone Y18008 with our clone revealed two different



**Fig. 5.** Expression of cP2X<sub>4</sub> receptor mRNA in different embryonic (day 10) chick tissues detected by Northern blot hybridization (**A**) and RT-PCR (**B**). **A:** For Northern blot analysis, 3 μg of polyA<sup>+</sup> RNA was loaded per lane in a 1.5% agarose gel and the X-ray film was exposed for 3 days. **B:** Touch-down PCR was run for 30 cycles. cP2X<sub>4</sub> cDNA (0.3 pg) was used as positive control. Molecular marker, 1 kb ladder from Promega Ltd.

sites in the sequence. When the amino acid sequence of Clone Y18008 is aligned with rat and human P2X<sub>4</sub> receptors, it is shown that Y18008 has one amino acid residue missing at position 128 of rat and human P2X<sub>4</sub> receptor sequences. In our clone that amino acid, an asparagine, does exist, which means the chick P2X<sub>4</sub> receptor polypeptide chain should have 385 amino acids instead of 384. Another different site is at amino acid 326 of the P2X<sub>4</sub> receptor; rat, human, mouse, and our chick P2X<sub>4</sub> clones all show that this residue is a conserved lysine, while clone Y18008 shows a residue of glutamate, which is due to the difference of a single nucleotide: a G in Clone Y18008 and an A in our clone.

Functional study of homomeric cP2X<sub>4</sub> receptors expressed in *Xenopus* oocytes revealed that cP2X<sub>4</sub> recep-



**Fig. 6.** Whole-mount in situ hybridization of day 4 chick embryo with digoxigenin-labeled cP2X<sub>4</sub> RNA probe. **A:** Lateral view of the whole embryo (Giz, gizzard). **B:** Section over the middle part of the embryo showing the expression of cP2X<sub>4</sub> RNA in spinal cord (SC), notochord (NC), and esophagus (Oes).

tors share many electrophysiological and pharmacological properties with rP2X<sub>4</sub> receptors, such as partial desensitization and insensitivity to  $\alpha,\beta$ -methyleneATP. The potency of ATP in activating cP2X<sub>4</sub> receptors is quite close to that of rP2X<sub>4</sub> receptor (10  $\mu$ M) and also close to the cP2X<sub>4</sub> reported by Ruppelt et al. [1999] ( $13.7 \pm 2.1 \mu$ M). For both chick and rat P2X<sub>4</sub> receptors, ATP was the most potent among the known P2X receptor agonists. However, 2-methylthioATP and ATP $\gamma$ S are much less potent on cP2X<sub>4</sub> than on rP2X<sub>4</sub>.

The commonly used P2X receptor antagonists, suramin, PPADS, and Reactive blue 2 all potentiated the ATP-induced currents via rP2X<sub>4</sub> receptors, whereas they blocked the hP2X<sub>4</sub> receptors [Garcia-Guzman et al., 1997]. Mouse P2X<sub>4</sub> receptors expressed in *Xenopus* oocytes were potentiated by the three antagonists [Townsend-Nicholson et al., 1999], whereas mP2X<sub>4</sub> receptors expressed in HEK 293 cells showed a different profile: they were effectively blocked by PPADS, but were still insensitive to suramin [Jones et al., 2000]. The difference in sensitivity to PPADS is probably because of the longer preincubation of PPADS before application

of ATP in the later study. Chick P2X<sub>4</sub> receptors were shown to be partially blocked by suramin and PPADS, which is different from both the rP2X<sub>4</sub> and hP2X<sub>4</sub> receptors. The structural determinants controlling the antagonist sensitivity have been explored before. A mutant of rP2X<sub>4</sub> produced by replacing amino acid 249 from glutamate to lysine was shown to be readily and irreversibly antagonized by PPADS [Buell et al., 1996]. However, this mutant was still not sensitive to suramin, indicating these two antagonists bind to different structures of the receptor protein. In another experiment, chimeras of rat and human P2X<sub>4</sub> receptors were generated to identify the domains responsible for the antagonist sensitivity [Garcia-Guzman et al., 1997]. It was also suggested that PPADS and suramin binds to different domains of the P2X<sub>4</sub> receptors.

TNP-ATP has been used as a fluorescent label for ATP binding sites in proteins [Mockett et al., 1994]. It has also been found to be a potent P2X receptor antagonist [Mockett et al., 1994; Virginio et al., 1998; Thomas et al., 1998]. Homomeric P2X<sub>1</sub> and P2X<sub>3</sub>, and heteromeric P2X<sub>2/3</sub> receptors are especially sensitive to TNP-ATP, with IC<sub>50</sub> values of 1–7 nM. Much higher concentrations of TNP-ATP were required to block P2X<sub>2</sub>, P2X<sub>4</sub>, and P2X<sub>7</sub> receptors, with IC<sub>50</sub> values >2  $\mu$ M [Virginio et al., 1998]. Homomeric cP2X<sub>4</sub> receptors were blocked by TNP-ATP with an IC<sub>50</sub> value of 4.74  $\mu$ M, about three times lower than the IC<sub>50</sub> value obtained on rP2X<sub>4</sub> receptors expressed in HEK293 cells (15.2  $\mu$ M) [Virginio et al., 1998]. On the other hand, cP2X<sub>8</sub> receptors are highly sensitive to TNP-ATP: 10 nM TNP-ATP completely blocked 10  $\mu$ M ATP-induced inward currents (data not shown). This might be due to the finding that cP2X<sub>8</sub> receptor has similar electrophysiological and pharmacological properties to P2X<sub>1</sub> and P2X<sub>3</sub> receptors, such as fast desensitization and sensitivity to  $\alpha,\beta$ -methyleneATP [Bo et al., 2000]. An IC<sub>50</sub> value for cP2X<sub>8</sub> receptor could not be obtained due to the prolonged recovery after the activation of the receptor.

With Northern blot hybridization and RT-PCR the expression of cP2X<sub>4</sub> mRNA transcripts was detected in all the tissues tested in day 10 chick embryos. Whole-mount in situ hybridization of day 3, 4, or 6 embryos also confirmed the expression of cP2X<sub>4</sub> mRNAs in a variety of organs. Although our cP2X<sub>4</sub> receptor was cloned from the skeletal muscle, the electrophysiological and pharmacological properties of the native P2X receptors in embryonic skeletal muscle are very much like those of cP2X<sub>8</sub> receptors [Bo et al., 2000]. The physiological function of cP2X<sub>4</sub> receptors in embryonic skeletal muscle remains to be elucidated. In embryonic chick neural retina, ATP receptor was reported to regulate the synthesis of DNA [Sugioka et al., 1999]. It is not clear whether P2X<sub>4</sub> receptor is involved in such a process, although cP2X<sub>4</sub> RNA is highly expressed in embryonic chick retina.

## ACKNOWLEDGMENTS

The work was supported by grants from the Wellcome Trust to GB and RS. The editorial work by Mr. R. Jordan in the preparation of the manuscript is greatly appreciated.

## REFERENCES

- Abbracchio MP, Burnstock G. 1994. Purinoceptors: are there families of P2X and P2Y purinoceptors? *Pharmacol Ther* 64:445–475.
- Bo X, Zhang Y, Nassar M, Burnstock G, Schoepfer R. 1995. A P2X purinoceptor cDNA conferring a novel pharmacological profile. *FEBS Lett* 375:129–133.
- Bo X, Schoepfer R, Burnstock G. 2000. Molecular cloning and characterization of a novel ATP P2X receptor subtype from embryonic chick skeletal muscle. *J Biol Chem* 275:14401–14407.
- Buell G, Lewis C, Collo G, North RA, Surprenant A. 1996. An antagonist-insensitive P2X receptor expressed in epithelia and brain. *EMBO J* 15:55–62.
- Burnstock G. 1997. The past, present and future of purine nucleotides as signalling molecules. *Neuropharmacology* 36:1127–1139.
- Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund PE, Stuhmer W. 1997. Characterization of recombinant human P2X<sub>4</sub> receptor reveals pharmacological differences to the rat homologue. *Mol Pharmacol* 51:109–118.
- Hume RI, Honig MG. 1986. Excitatory action of ATP on embryonic chick muscle. *J Neurosci* 6:681–690.
- Jones CA, Chessell IP, Simon J, Barnard EA, Miller KJ, Michel AD, Humphrey PPA. 2000. Functional characterization of the P2X<sub>4</sub> receptor orthologues. *Br J Pharmacol* 129:388–394.
- Kolb HA, Wakelam MJ. 1983. Transmitter-like action of ATP on patched membranes of cultured myoblasts and myotubes. *Nature* 303:621–623.
- Lê KT, Babinski K, Séguéla P. 1998. Central P2X<sub>4</sub> and P2X<sub>6</sub> channel subunits coassemble into a novel heteromeric ATP receptor. *J Neurosci* 18:7152–7159.
- MacKenzie AB, Surprenant A, North RA. 1999. Functional and molecular diversity of purinergic ion channel receptors. *Ann NY Acad Sci* 868:716–729.
- Mockett BG, Housley GD, Thorne PR. 1994. Fluorescence imaging of extracellular purinergic receptor sites and putative ecto-ATPase sites on isolated cochlear hair cells. *J Neurosci* 14:6992–7007.
- Naemtsch LN, Weidema AF, Sims SM, Underhill TM, Dixon SJ. 1999. P2X(4) purinoceptors mediate an ATP-activated, non-selective cation current in rabbit osteoclasts. *J Cell Sci* 112:4425–4435.
- Nieto MA, Patel K, Wilkinson DG. 1996. In situ hybridization analysis of chick embryos in whole mount and tissue sections. *Methods Cell Biol* 51:219–235.
- Ralevic V, Burnstock G. 1998. Receptors for purines and pyrimidines. *Pharmacol Rev* 50:413–492.
- Ruppelt A, Liang BT, Soto F. 1999. Cloning, functional characterization and developmental expression of a P2X receptor from chick embryo. *Prog Brain Res* 120:81–90.
- Séguéla P, Haghghi A, Soghomonian JJ, Cooper E. 1996. A novel neuronal P2x ATP receptor ion channel with widespread distribution in the brain. *J Neurosci* 16:448–455.
- Soto F, Garcia-Guzman M, Gomez-Hernandez JM, Hollmann M, Karschin C, Stuhmer W. 1996. P2X<sub>4</sub>: an ATP-activated ionotropic receptor cloned from rat brain. *Proc Natl Acad Sci USA* 93:3684–3688.
- Sugioka M, Zhou WL, Hofmann HD, Yamashita M. 1999. Involvement of P2 purinoceptors in the regulation of DNA synthesis in the neural retina of chick embryo. *Int J Dev Neurosci* 17:135–144.
- Thomas S, Virginio C, North RA, Surprenant A. 1998. The antagonist trinitrophenyl-ATP reveals co-existence of distinct P2X receptor channels in rat nodose neurons. *J Physiol Lond* 509:411–417.
- Townsend-Nicholson A, King BF, Wildman SS, Burnstock G. 1999. Molecular cloning, functional characterization and possible cooperativity between the murine P2X<sub>4</sub> and P2X<sub>4a</sub> receptors. *Brain Res Mol Brain Res* 64:246–254.
- Virginio C, Robertson G, Surprenant A, North RA. 1998. Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X<sub>1</sub>, P2X<sub>3</sub>, and heteromeric P2X<sub>2/3</sub> receptors. *Mol Pharmacol* 53:969–973.
- Wang CZ, Namba N, Gono T, Inagaki N, Seino S. 1996. Cloning and pharmacological characterization of a fourth P2X receptor subtype widely expressed in brain and peripheral tissues including various endocrine tissues. *Biochem Biophys Res Commun* 220:196–202.
- Xiang Z, Bo X, Burnstock G. 1998. Localization of ATP-gated P2X receptor immunoreactivity in rat sensory and sympathetic ganglia. *Neurosci Lett* 256:105–108.